Last week, we hosted the most engaging event I’ve been a part of here at Endpoints News. If you were there, you got to see a showdown of ideas between some of the most important voices in biopharma: We debated the rise of China, the US response and how it will shape the global future of biotech for patients, companies, governments, founders and investors. It got intense at times, but it was also a ton of fun. If you missed it (or if you want to relive it), we’re making the audio and video recordings available here: Has China changed how we build companies? Roivant CEO Matt Gline + Strand Therapeutics CEO/Founder Jacob Becraft Investor math versus industrial priorities, with RA Capital Managing Partner/Founder Peter Kolchinsky, MIT Professor Fiona Murray and Ginkgo Bioworks CEO Jason Kelly What big pharma wants from China, with Pfizer Special Advisor Andrew Baum You can also find them on our Apple Podcasts and Spotify pages (and you can subscribe there to get future shows). One thing Thursday’s debates made clear: This is only the beginning of the conversation. That’s why we’re going to be back in mid-September for round two — this time in Washington, DC — where we’ll focus on policy and national security. Stay tuned for more details soon. Thanks for joining us, and for listening and watching, — Drew Armstrong, Executive Editor